Almirall Patent-Cliff Exposure & CMS Drug Spending Portfolio
Almirall (US): 6 reconciled FDA prescription therapies (0.2% 2025 to 2030 cliff risk), $9.2M 2024 CMS Part D & Medicaid spend, and $1,556 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 6 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.2% |
| Primary Portfolio LOE Date | 2027-01-01 |
| 2024 CMS Total Public Spend | $9.2M |
| 2024 Medicare Part D Spend | $9.2M |
| 2024 Medicaid Spend | $0 |
| California HCAI SB 17 Filings | Specialty launch notice ($1,556 intro WAC) |